Molnupiravir (EIDD-2801) CAS 2349386-89-4 COVID-19 API Kounga Teitei
Molnupiravir Hokohoko me nga Kaiwaenga e Pa ana me te Kounga Kairangi
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Ingoa matū | Molnupiravir (EIDD-2801) |
| Nga kupu taurite | MK-4482;β-D-N4-Hydroxycytidine-5′-isopropyl ester;((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2 -yl) methyl isobutyrate |
| Tau CAS | 2349386-89-4 |
| Tau CAT | RF-API97 |
| Tūnga Taonga | Kei roto i nga taonga, ka eke ki te rau kirokaramu |
| Tātai rāpoi | C13H19N3O7 |
| Taumaha rāpoi | 329.31 |
| Wairewa | Wairewa i roto i te DMSO |
| Waitohu | Ruifu Chemical |
| Tūemi | Whakatakotoranga |
| Te ahua | Ma ki te Paura-White |
| Tautuhinga IR | He rite te Tauira Spectrum ki te paerewa tohutoro |
| Tautuhinga HPLC | Ko te wa pupuri o te tihi nui o te otinga tauira e rite ana ki tera o te otinga paerewa |
| Nga Taonga Paanga | |
| Te poke A | ≤0.15% |
| Te poke B | ≤0.15% |
| Tetahi poke kore i tohua | ≤0.15% |
| Tapeke poke kore i tohua | ≤0.30% |
| Nga poke katoa | ≤0.50% |
| Wairewa toenga | |
| N-Heptane | ≤5000ppm |
| Ewaro | ≤5000ppm |
| Isopropyl Acetate | ≤5000ppm |
| Acetonitrile | ≤410ppm |
| Methylene Dichloride | ≤600ppm |
| Acetone | ≤5000ppm |
| Isopropanol | ≤5000ppm |
| Ihirangi wai (KF) | ≤0.50% |
| Te toenga i runga i te mura | ≤0.10% |
| Te hurihanga whatu | -7.5° ki te -9.5° (C=0.5, Mewaro) |
| Nga Korewa Taamaha | ≤10ppm |
| Te Maama / Tikanga Tatauria | ≥99.5% (230nm) |
| Tikanga Whakamatau / Tatau | 98.0%~102.0% (HPLC i runga i te tikanga maroke) |
| Te Ora Papa | 24 Marama |
| Paerewa Whakamatau | Paerewa hinonga |
| Whakamahinga | API, Molnupiravir (EIDD-2801) COVID-19 Inhibitor |
Mōkī: Pounamu, Peeke konumohe konumohe, Pahu Kaata, 25kg / Drum, kia rite ranei ki te hiahia a te kaihoko.
Tikanga Rokiroki:Whakaorangia i roto i nga ipu kua hiri ki te waahi makariri me te maroke;Whakaorangia mai i te marama, te makuku me te mate kino.
Ko te Molnupiravir (EIDD-2801, MK-4482) he prodrug bioavailable a-waha o te ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) me te mahi antiviral whanui whanui ki te SARS-CoV-2, MERS-CoV, SARS-CoV, me te kaikorero o te COVID-19.Kei te hokona a Molnupiravir i raro i te ingoa tohu Lagevrio me te tikanga he emorivir.Kua whakaatuhia te Molnupiravir ki te whakapai ake i nga mahi o te puku, ki te whakaheke i te taumaha o te tinana me te whakaiti i te nui o te huaketo i roto i te puku.I tua atu i te mahi ki nga coronaviruses, Molnupiravir, i roto i nga rangahau taiwhanga, kua whakaatu i te mahi ki te rewharewha o te tau me te rewharewha manu, te mate rewharewha syncytial, te huaketo chikungunya, te huaketo Ebola, te huaketo encephalitis equine Venezuelan, me te huaketo encephalitis equine Eastern.I whakawhanakehia tuatahi a Molnupiravir ki te rongoa i te rewharewha i te Whare Wananga o Emory e te kamupene whakangao tarukino o te whare wananga, Drug Innovation Ventures i Emory (DRIVE), engari e kii ana i whakarerea mo nga awangawanga mutagenicity.I hokona e te kamupene Ridgeback Biotherapeutics o Miami, i mahi tahi me Merck & Co. ki te whakawhanake ake i te tarukino.I whakaaetia a Molnupiravir mo te whakamahi rongoa i te United Kingdom i te Whiringa-a-rangi 2021.
